BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioAtla's operating income for the twelve months ending Jun 30, 2026 was -$32.13M. For fiscal 2025 it was -$59.31M. The highest annual figure on record is -$28.27M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.31M | – |
| FY2024 | Dec 31, 2024 | -$73.94M | – |
| FY2023 | Dec 31, 2023 | -$129.69M | – |
| FY2022 | Dec 31, 2022 | -$108.14M | – |
| FY2021 | Dec 31, 2021 | -$96.44M | – |
| FY2020 | Dec 31, 2020 | -$30.10M | – |
| FY2019 | Dec 31, 2019 | -$28.27M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $227.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.35M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.52M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.11M | – |
See a number that looks wrong?